Robbins LLP reminded investors that Nov. 2, 2026, is the deadline to seek appointment as lead plaintiff in a putative securities class action involving Unicycive Therapeutics, Inc. securities purchased or otherwise acquired from Dec. 29, 2025, through June 29, 2026. The complaint alleges that Unicycive failed to inspect or audit a third-party manufacturing facility after the FDA cited deficiencies there, leaving the company without a reasonable basis to say the issues had been resolved. The lawsuit followed Unicycive’s June 30 disclosure that the FDA had issued a CRL concerning its resubmitted NDA for oxylanthanum carbonate, or OLC, citing the same manufacturing deficiencies identified in June 2025. Unicycive shares fell $3.01, or 39.1%, to close at $4.69 on June 30. Investors who do not seek lead plaintiff status may remain absent class members if the case proceeds, and Robbins LLP says it represents investors on a contingency fee basis.